Dx Deals: Profusa Trying to Buy G3 Vision Labs in Unusual $455 Million Stock Deal
If Profusa pulls off the purchase, it will give the startup its first revenue source
Already a member? Log in here
Author Information
Ron Shinkman
Ron Shinkman is a veteran journalist and editor with more than 20 years of experience in the healthcare business realm. He served as Los Angeles bureau chief of Modern Healthcare and also wrote for the Los Angeles and Orange County Business Journals.
Posts by the Author
FDA Watch: Labcorp Gets Companion Diagnostic Approval for Advanced Melanoma Test
Company also announces distribution of newly approved Alzheimer’s assay
Already a member? Log in here
Diagnostics Pipeline: Cizzle Bio Introduces Test for Earlier Lung Cancer Detection
The CIZ1B biomarker blood-based assay has 95% sensitivity for detecting earliest stage of the cancer
Already a member? Log in here
FDA Watch: OraSure’s Collection Device for Cobas STI Testing Receives Approval
At-home sample collections can be mailed to a clinical laboratory
Already a member? Log in here
Dx Deals: Danaher Acquires StatLab in Deal Valued at More than $1 Billion
The company will fold into Leica Biosystems after the transaction closes at the end of this year
Already a member? Log in here
Diagnostics Pipeline: Xella Health Launches Platform Focused on Women’s Medical Issues
The startup is trying to close the care gap between female and male patients
Already a member? Log in here
Dx Deals: Labcorp Quietly Buys Tribal Diagnostics
Acquisition likely isn’t a full-blown push into Native American healthcare, consultant Larry Worden says
Already a member? Log in here
FDA Watch: Zepto Life Technology Receives FDA Breakthrough Designation for Blood-Based Mold Test
Its FungiFlex assay can make determining the cause of fungal infections vastly more accurate
Already a member? Log in here
Diagnostics Pipeline: Expanded DPYD Test Anticipated to Make Chemotherapy Safer
Labcorp’s new genotyping test can identify gene variants that may make standard oncologic treatment deadly for some
Already a member? Log in here
FDA Watch: Natera, Valar Labs Receive FDA Clearances for Bladder Cancer Tests
Natera’s assay focuses on the need for adjuvant therapy, while Valar’s test stratifies risk of recurrence
Already a member? Log in here
